All eyes are focused on the Supreme Court as it extended its administrative stay on a lower court ruling that would restrict the availability of abortion pill mifepristone until Friday at midnight. The extension will give the higher court an extra few days to decide what to do with the ruling, which could limit access to the pill even in states where abortion is legal. (NPR)
Lawmakers on Capitol Hill released a bipartisan framework that lays out reforms for pharmacy benefit managers. The policy solutions proposed would aim to improve transparency among PBMs and tackle their practices that may drive up drug costs. (Endpoints News)
The Pan American Health Organization is in talks with Takeda about its dengue vaccine amid a massive outbreak in the region. In a recent study, Takeda’s QDENGA vaccine showed it could prevent 61% of dengue infections and 85% of severe cases. (Reuters)
The rate of mild autism cases has risen faster than cases of “profound” autism, according to a recent study. The study found that while profound diagnoses increased to about five cases per 1,000, the rate of mild autism cases grew to 14 per 1,000. (ABC News)
A U.S. appeals court ruling in favor of Amgen will keep a generic psoriasis drug challenging Otezla off the market until 2028. The Federal Circuit also upheld a decision to invalidate one of Amgen’s patents that Sandoz said would have barred its generics until 2034. (Bloomberg)
